You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameInterferon beta-1a
Accession NumberDB00060  (BTD00093, BIOD00093)
TypeBiotech
GroupsApproved, Investigational
DescriptionHuman interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Protein structureDb00060
Related Articles
Protein chemical formulaC908H1408N246O252S7
Protein average weight20027.0 Da
Sequences
>DB00060 sequence
MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIY
EMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSL
HLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
Download FASTA Format
Synonyms
Fibroblast interferon
IFN-beta
Interferon beta precursor
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AvonexKitIntramuscularBiogen Idec Inc.2014-08-29Not applicableUs
AvonexPowder, for solution60 mcgIntramuscularBiogen Canada IncNot applicableNot applicableCanada
AvonexInjection, solution30 ug/.5mLIntramuscularBiogen Idec Inc.2003-05-232015-12-29Us
AvonexKitIntramuscularBiogen Idec Inc.2014-08-29Not applicableUs
AvonexKitIntramuscularBiogen Idec Inc.2014-08-29Not applicableUs
AvonexSolution30 mcgIntramuscularBiogen Canada Inc2005-12-02Not applicableCanada
AvonexInjection, powder, lyophilized, for solution30 ug/mLIntramuscularBiogen Idec Inc.1996-05-172015-12-29Us
Avonex PenInjection, solution30 ug/.5mLIntramuscularBiogen Idec Inc.2003-05-232015-12-29Us
RebifSolution44 mcgSubcutaneousEmd Serono A Division Of Emd Inc Canada1998-02-24Not applicableCanada
RebifInjection, solution44 ug/.5mLSubcutaneousEMD Serono, Inc.2002-03-07Not applicableUs
RebifKitSubcutaneousEMD Serono, Inc.2004-12-17Not applicableUs
RebifSolution66 mcgSubcutaneousEmd Serono A Division Of Emd Inc Canada2009-05-14Not applicableCanada
RebifSolution132 mcgSubcutaneousEmd Serono A Division Of Emd Inc CanadaNot applicableNot applicableCanada
RebifSolution132 mcgSubcutaneousEmd Serono A Division Of Emd Inc Canada2009-05-14Not applicableCanada
RebifSolution22 mcgSubcutaneousEmd Serono A Division Of Emd Inc Canada1998-02-23Not applicableCanada
RebifSolution8.8 mcgSubcutaneousEmd Serono A Division Of Emd Inc Canada2006-05-302013-08-09Canada
RebifInjection, solution22 ug/.5mLSubcutaneousEMD Serono, Inc.2002-03-07Not applicableUs
Rebif RebidoseKitSubcutaneousEMD Serono, Inc.2012-12-21Not applicableUs
Rebif RebidoseInjection, solution22 ug/.5mLSubcutaneousEMD Serono, Inc.2012-12-21Not applicableUs
Rebif RebidoseInjection, solution44 ug/.5mLSubcutaneousEMD Serono, Inc.2012-12-21Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetaferonBayer
BlastoferonSidus
UribetaProbiomed
Brand mixtures
NameLabellerIngredients
AvonexBiogen Canada Inc
RebifEmd Serono A Division Of Emd Inc Canada
SaltsNot Available
Categories
UNIIXRO4566Q4R
CAS number145258-61-3
Pharmacology
IndicationFor treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
Structured Indications
PharmacodynamicsInterferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin.
Mechanism of actionInterferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
TargetKindPharmacological actionActionsOrganismUniProt ID
Interferon alpha/beta receptor 1Proteinyes
agonist
HumanP17181 details
Interferon alpha/beta receptor 2ProteinyesNot AvailableHumanP48551 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life10 hrs
Clearance
  • 33-55 L/hour [Healthy SC injection of 60 mcg]
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon beta-1a.Experimental
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Interferon beta-1a.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Interferon beta-1a.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1a.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Interferon beta-1a.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Interferon beta-1a.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1a.Approved, Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Interferon beta-1a.Approved
OuabainOuabain may decrease the cardiotoxic activities of Interferon beta-1a.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1a.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Interferon beta-1a.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Zidovudine.Approved
Food InteractionsNot Available
References
Synthesis Reference

Heinz-Jurgen Friesen, Sidney Pestka, “Preparation of homogeneous human fibroblast interferon.” U.S. Patent US4289689, issued December, 1968.

US4289689
General ReferencesNot Available
External Links
ATC CodesL03AB07
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (63 KB)
MSDSNot Available
Pharmacoeconomics
Manufacturers
  • Biogen Idec
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular30 ug/mL
Injection, solutionIntramuscular30 ug/.5mL
KitIntramuscular
Powder, for solutionIntramuscular
Powder, for solutionIntramuscular60 mcg
SolutionIntramuscular30 mcg
Injection, solutionSubcutaneous22 ug/.5mL
Injection, solutionSubcutaneous44 ug/.5mL
Kit; liquid; powderIntralesional; Subcutaneous
Kit; liquid; powder, for solutionSubcutaneous
SolutionSubcutaneous132 mcg
SolutionSubcutaneous22 mcg
SolutionSubcutaneous44 mcg
SolutionSubcutaneous66 mcg
SolutionSubcutaneous8.8 mcg
KitSubcutaneous
Prices
Unit descriptionCostUnit
Avonex 4 30 mcg/vial Kit 1 Box = 4 Vials ( 0.5ml Per Vial)3252.29USD box
Avonex Prefilled (1 Box = 1 Kit = Four 30 mcg/0.5ml Syringes) Box3252.29USD box
Avonex admin pack 30 mcg vial781.8USD vial
Rebif 22 mcg/0.5 ml syringe247.79USD syringe
Rebif 44 mcg/0.5 ml syringe247.79USD syringe
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341604 No2010-05-042027-05-04Canada
Properties
StateLiquid
Experimental Properties
PropertyValueSource
hydrophobicity-0.427Not Available
isoelectric point8.93Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Type i interferon receptor activity
Specific Function:
Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.
Gene Name:
IFNAR1
Uniprot ID:
P17181
Molecular Weight:
63524.81 Da
References
  1. Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44. [PubMed:10049744 ]
  2. van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15. [PubMed:16912135 ]
  3. Dupont SA, Goelz S, Goyal J, Green M: Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res. 2002 Apr;22(4):491-501. [PubMed:12034032 ]
  4. Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS: Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001 Nov;21(11):931-41. [PubMed:11747625 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Type i interferon receptor activity
Specific Function:
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.
Gene Name:
IFNAR2
Uniprot ID:
P48551
Molecular Weight:
57758.24 Da
References
  1. van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15. [PubMed:16912135 ]
  2. Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS: Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001 Nov;21(11):931-41. [PubMed:11747625 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23